Shire PLC (LON:SHP) Rating Reiterated
Shire PLC (LON:SHP) had its stock rating noted as Overweight by analysts at JP Morgan Cazenove. JP Morgan Cazenove currently has a GBX 6600.00 target price per share on the 33.42B GBP market cap company or 19.46% upside potential. This was disclosed in analysts note on Friday, 24 July.
LON:SHP is right now trading -0.71% lower at GBX 5600.00 as of 08:21 London time. Shire PLC’s stock is up 51.98% in the last 200 days. It has outperformed the S&P 500, which has added 6.99% in the same time period.
According to data compiled by Thomson Reuters, Shire PLC (LON:SHP)’s stock is covered by 17 equity analysts across the Street, with 1 analysts giving it a Sell rating, 15 a Buy rating, while 6 consider it a Hold. The 12-month consensus target price for the stock is GBX 9374, which reflects an upside potential of 66.21% over the current price.
LON:SHP Price Chart & Trend
The stock price of Shire PLC went up 51.98% over the last 200 days, and is in reinforcing up trend. In the last 50 and 100 days, Shire PLC is up 6.46% and up 8.67%, respectively. Our stocks momentum model is shown on the price chart below.
Shire PLC (LON:SHP) Profile
Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas.
Shire PLC (LON:SHP) traded down -0.71% on 24 July, hitting GBX 5600. A total of 24,274 shares of the company’s stock traded hands. This is down from average of 1.08 million shares. Shire PLC has a 52 week low of GBX 3448.28 and a 52 week high of GBX 5755.00. The company has a market cap of 33.42 billion GBP and a P/E ratio of 14.89.
Get the latest Shire PLC (LON:SHP) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.